ReviewWorld journal of gastroenterology2018
New therapeutic options opened by the molecular classification of gastric cancer.
Review in World journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 41 citations in OpenAlex.
- A sweet danger: the silent link between hyperinsulinemia and gastric cancer.Molecular cancer · 2026Review
- NADPH-Related Enzymes and Cancer: Facts and Insights Into the Application of Immunohistochemistry.Biochemistry research international · 2026Review
- Understanding metastatic patterns in gastric cancer: Insights from lymph node distribution and pathology.World journal of gastrointestinal oncology · 2025Article
- Expression of programmed cell death ligand 1 protein and other biomarkers in patients with gastric cancer and gastroesophageal junction cancer: a retrospective single centre study in Brazil.Frontiers in oncology · 2025Article
- The Impact of Transcriptional Profiling Cadherin Family and Therapeutic Approaches of Gastric Cancer: A Translational Outlook on Multi-omics Data Analysis.Applied biochemistry and biotechnology · 2024Article
- Landscape of Innovative Methods for Early Diagnosis of Gastric Cancer: A Systematic Review.Diagnostics (Basel, Switzerland) · 2023Review
- Pregnancy and Gastric Cancer: A Narrative Review.Diagnostics (Basel, Switzerland) · 2023Review
- HTA and Gastric Cancer: Evaluating Alternatives in Third- and Fourth-Line Patients.International journal of environmental research and public health · 2023Article
- Effects ofOpen life sciences · 2023Article
- Signaling pathways and therapeutic interventions in gastric cancer.Signal transduction and targeted therapy · 2022Review
- Review
- Characterization of Platelet Function-Related Gene Predicting Survival and Immunotherapy Efficacy in Gastric Cancer.Frontiers in genetics · 2022Article
- Identification of potential targets of triptolide in regulating the tumor microenvironment of stomach adenocarcinoma patients using bioinformatics.Bioengineered · 2021Article
- TTPAL promotes gastric tumorigenesis by directly targeting NNMT to activate PI3K/AKT signaling.Oncogene · 2021Article
- Article
- Histological differentiation impacts the tumor immune microenvironment in gastric carcinoma: Relation to the immune cycle.World journal of gastroenterology · 2021Article
- Unusual immunohistochemical "null" pattern of four mismatch repair proteins in gastric cancer: A case report.World journal of clinical cases · 2021Article
- Her2-Positive and Microsatellite Instability Status in Gastric Cancer-Clinicopathological Implications.Diagnostics (Basel, Switzerland) · 2021Article
- Cell-free tumour DNA analysis detects copy number alterations in gastro-oesophageal cancer patients.PloS one · 2021Article
- Improvement in the Mortality-to-Incidence Ratios for Gastric Cancer in Developed Countries With High Health Expenditures.Frontiers in public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) is one of the most lethal and aggressive cancers, being the third cause of cancer related death worldwide. Even with radical gastrectomy and the latest generation of molecular chemotherapeutics, the numbers of recurrence and mortality remains high. This is due to its biological heterogeneity based on the interaction between multiple factors, from genomic to environmental factors, diet or infections with various pathogens. Therefore, understanding the molecular characteristics at a genomic level is critical to develop new treatment strategies. Recent advances in GC molecular classification provide the unique opportunity to improve GC therapy by exploiting the biomarkers and developing novel targeted therapy specific to each subtype. This article highlights the molecular characteristics of each subtype of gastric cancer that could be considered in shaping a therapeutic decision, and also presents the completed and ongoing clinical trials addressed to those targets. The implementation of the novel molecular classification system will allow a preliminary patient selection for clinical trials, a mandatory issue if it is desired to test the efficacy of a certain inhibitor to the given target. This will represent a substantial advance as well as a powerful tool for targeted therapy. Nevertheless, translating the scientific results into new personalized treatment opportunities is needed in order to improve clinical care, the survival and quality of life of patients with GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.